tiprankstipranks
Trending News
More News >
Precision BioSciences (DTIL)
NASDAQ:DTIL
Advertisement

Precision BioSciences (DTIL) AI Stock Analysis

Compare
762 Followers

Top Page

DTIL

Precision BioSciences

(NASDAQ:DTIL)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 4o)
Rating:44Neutral
Price Target:
$4.50
▼(-8.72% Downside)
The overall stock score of 44 reflects significant financial challenges, particularly in revenue decline and profitability issues. Technical analysis indicates a neutral trend with weak momentum, while valuation metrics are unattractive due to negative earnings and lack of dividends. These factors collectively result in a low stock score.
Positive Factors
Proprietary Technology
ARCUS technology offers a competitive edge in gene editing, enabling precise DNA edits. This can drive long-term growth through innovative therapies.
Strategic Partnerships
Strategic partnerships provide financial support and enhance research capabilities, facilitating sustainable revenue streams and innovation.
Low Leverage
Low leverage indicates financial stability and flexibility, allowing the company to invest in growth opportunities without significant debt burden.
Negative Factors
Revenue Decline
A sharp revenue decline suggests challenges in maintaining market demand and competitiveness, potentially impacting long-term financial health.
Profitability Issues
Negative profit margins indicate ongoing financial struggles, limiting the ability to reinvest in business growth and innovation.
Cash Flow Challenges
Negative cash flow highlights liquidity issues, potentially constraining operational flexibility and investment in future projects.

Precision BioSciences (DTIL) vs. SPDR S&P 500 ETF (SPY)

Precision BioSciences Business Overview & Revenue Model

Company DescriptionPrecision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
How the Company Makes MoneyPrecision BioSciences generates revenue through a combination of partnerships, collaborations, and licensing agreements. The company often enters into strategic alliances with pharmaceutical companies to co-develop therapies, which can provide upfront payments, research funding, and milestone payments as specific development goals are achieved. Additionally, Precision BioSciences may receive royalties on future product sales resulting from these collaborations. The company also pursues grant funding and may generate revenue from its proprietary technology through licensing deals, allowing others to utilize its ARCUS genome editing platform in their own research and development efforts.

Precision BioSciences Financial Statement Overview

Summary
Precision BioSciences faces significant financial challenges, particularly in profitability and cash flow. The company has a solid gross profit margin but struggles with negative earnings and cash flow generation. Despite a strong cash position, declining equity and inconsistent revenue growth pose risks. Overall, financial stability and growth trajectory are concerns that need addressing.
Income Statement
20
Very Negative
The company shows fluctuating revenue with recent declines, as seen in the TTM (Trailing-Twelve-Months) figures. Gross profit margin is solid, but negative EBIT and net income margins indicate operational and profitability challenges. Revenue growth has been inconsistent with a significant drop in the latest TTM period.
Balance Sheet
35
Negative
The company maintains a strong cash position relative to debt, indicating low leverage. However, stockholders' equity has decreased over time, and the equity ratio reflects a relatively weak capital structure. Debt-to-equity ratio is manageable, but the decline in equity is concerning.
Cash Flow
25
Negative
Free cash flow remains negative, with little improvement over time. Operating cash flow is consistently negative, indicating challenges in core business profitability. The operating cash flow to net income ratio is unfavorable, reflecting cash generation issues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.26M68.70M48.73M25.10M115.53M24.29M
Gross Profit565.00K68.70M40.47M16.09M115.53M24.29M
EBITDA-73.73M13.53M-32.04M-62.79M-20.27M-99.19M
Net Income-78.25M7.17M-61.32M-122.91M-30.92M-109.01M
Balance Sheet
Total Assets108.93M136.39M159.78M238.17M211.50M150.16M
Cash, Cash Equivalents and Short-Term Investments62.24M86.31M116.68M189.58M143.66M89.80M
Total Debt29.45M30.05M31.27M27.04M9.11M10.52M
Total Liabilities74.87M80.00M140.92M177.74M120.33M105.73M
Stockholders Equity34.05M56.39M18.86M60.43M91.17M44.42M
Cash Flow
Free Cash Flow-64.12M-58.70M-86.39M-49.07M-16.66M-92.42M
Operating Cash Flow-63.92M-58.45M-84.11M-45.75M-10.85M-87.39M
Investing Cash Flow-487.00K-215.00K5.83M-3.32M-5.80M-5.03M
Financing Cash Flow25.64M50.45M5.39M94.98M70.52M1.33M

Precision BioSciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.93
Price Trends
50DMA
4.82
Positive
100DMA
4.82
Positive
200DMA
4.94
Positive
Market Momentum
MACD
0.01
Negative
RSI
57.85
Neutral
STOCH
71.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Positive. The current price of 4.93 is above the 20-day moving average (MA) of 4.90, above the 50-day MA of 4.82, and below the 200-day MA of 4.94, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 57.85 is Neutral, neither overbought nor oversold. The STOCH value of 71.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DTIL.

Precision BioSciences Risk Analysis

Precision BioSciences disclosed 73 risk factors in its most recent earnings report. Precision BioSciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Precision BioSciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
397.44M4.97-6988.82%18.01%306.76%
44
Neutral
$60.47M2.40-143.89%-98.56%-347.81%
41
Neutral
89.45M-1.02-100.00%55.32%
36
Underperform
49.07M-0.6918.86%
27
Underperform
71.16M-0.6448.45%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DTIL
Precision BioSciences
4.93
-4.12
-45.52%
BLUE
Bluebird Bio
4.97
-5.12
-50.74%
CTMX
CytomX Therapeutics
2.84
1.64
136.67%
ACET
Adicet Bio
0.84
-0.59
-41.26%
IMA
ImageneBio
7.78
-12.98
-62.52%
ACRV
Acrivon Therapeutics, Inc.
1.54
-5.62
-78.49%

Precision BioSciences Corporate Events

Executive/Board Changes
Precision BioSciences Updates Executive Employment Agreements
Neutral
Sep 2, 2025

On August 26, 2025, Precision BioSciences amended and restated employment agreements for its key executives to retain them and reflect updated compensation terms. These agreements include provisions for termination without cause and require funding of severance and expenses in an escrow account, with interest and unused funds benefiting the company.

The most recent analyst rating on (DTIL) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
Precision BioSciences Reports Promising Phase 1 Trial Results
Positive
Aug 6, 2025

On August 6, 2025, Precision BioSciences announced results from its Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, a treatment for hepatitis B. The trial’s Cohort 1, which involved three patients receiving low-dose PBGENE-HBV, showed promising safety and efficacy results, with no serious adverse events and significant reductions in hepatitis B surface antigen levels. Cohort 2 is underway, with one patient completing three doses and two others receiving one dose each, showing similar safety profiles. The favorable outcomes have led to the recommendation to initiate Cohort 3, with further updates expected later in 2025.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 23, 2025